The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
 
Jacob J. Chabon
No Relationships to Disclose
 
Andrew Simmons
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Consulting or Advisory Role - Redwood Bioscience
 
Aaron M. Newman
Stock and Other Ownership Interests - CAPP Medical
Consulting or Advisory Role - Roche
Patents, Royalties, Other Intellectual Property - Stanford University
 
Alexander F. Lovejoy
Employment - Roche
 
Mohammad S Esfahani
No Relationships to Disclose
 
Henry Haringsma
No Relationships to Disclose
 
David Matthew Kurtz
No Relationships to Disclose
 
Henning Stehr
No Relationships to Disclose
 
Florian Scherer
No Relationships to Disclose
 
Kathleen A. Durkin
No Relationships to Disclose
 
Gregory Alan Otterson
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Ignyta (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Xcovery (Inst)
 
William T. Purcell
No Relationships to Disclose
 
D. Ross Camidge
No Relationships to Disclose
 
Jonathan Wade Goldman
Honoraria - Clovis Oncology; Genentech
Research Funding - ArQule; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Synta
 
Lecia V. Sequist
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology
 
Heather A. Wakelee
Honoraria - ACEA Biosciences; Biocon; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Consulting or Advisory Role - ACEA Biosciences; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - ACEA Biosciences; Clovis Oncology; Novartis; Pfizer
 
Joel W. Neal
Consulting or Advisory Role - Boehringer Ingelheim; CARET; Clovis Oncology; Nektar
Research Funding - ArQule; Boehringer Ingelheim; Exelixis; Genentech/Roche; Merck; Nektar; Novartis
 
Ash A. Alizadeh
Employment - Stanford University Cancer Institute
Leadership - Lymphoma Research Foundation
Stock and Other Ownership Interests - Roche
Honoraria - Roche
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche/Genentech
Research Funding - Celgene
 
Maximilian Diehn
Stock and Other Ownership Interests - CAPP Medical; Quanticel Pharma
Consulting or Advisory Role - Novartis; Quanticel Pharma; Roche Molecular Diagnostics
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Royalties from patents licensed to Quanticel Pharmaceuticals
Travel, Accommodations, Expenses - Novartis; Roche Molecular Diagnostics